Researchers Use NIV Methods for Diagnosis of Endometrial Cancer
By LabMedica International staff writers Posted on 01 Jul 2019 |
Image: Non-invasive sampling methods are being considered as the basis for genomic diagnosis of endometrial cancer (Photo courtesy of Medical News Today).
A team of Catalan cancer researchers has suggested using materials containing biomarkers and cellular debris collected during routine Pap smears and other non-invasive sampling methods as the basis for genomic diagnosis of endometrial cancer.
Currently, methods for detecting endometrial cancer are limited to high-risk populations and symptomatic women, since 90% of endometrial cancers present with abnormal bleeding. To improve this situation, investigators at Bellvitge Biomedical Research Institute (Barcelona, Spain) and collaborators in Catalonia and abroad suggested taking advantage of the anatomical continuity of the uterine cavity with the cervix. By doing so, they suggested the possibility of genomic exploitation of material from routine, non-invasive sampling methods. This would represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract.
The investigators have taken initial steps in this process by recruiting nearly 500 female subjects and gathering more than 1,600 biological samples for analysis.
Certain questions remain to be addressed in order to accelerate the implementation of novel technologies for routine screening in a clinical setting. In this regard, the investigators discussed new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods in a paper published in the June 19, 2019, online edition of the International Journal of Cancer.
Related Links:
Bellvitge Biomedical Research Institute
Currently, methods for detecting endometrial cancer are limited to high-risk populations and symptomatic women, since 90% of endometrial cancers present with abnormal bleeding. To improve this situation, investigators at Bellvitge Biomedical Research Institute (Barcelona, Spain) and collaborators in Catalonia and abroad suggested taking advantage of the anatomical continuity of the uterine cavity with the cervix. By doing so, they suggested the possibility of genomic exploitation of material from routine, non-invasive sampling methods. This would represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract.
The investigators have taken initial steps in this process by recruiting nearly 500 female subjects and gathering more than 1,600 biological samples for analysis.
Certain questions remain to be addressed in order to accelerate the implementation of novel technologies for routine screening in a clinical setting. In this regard, the investigators discussed new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods in a paper published in the June 19, 2019, online edition of the International Journal of Cancer.
Related Links:
Bellvitge Biomedical Research Institute
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access